Australasian Nanoparticle-mediated Magnetically Enhanced Diffusion for Ischemic Stroke

Inclusion Criteria: * Patients presenting with ischemic stroke within 24 hours of the time they were last known to be well * Patient's age is ≥18 years * Legal requirements for consent as per local legislative requirements are satisfied. * Distal medium vessel intracranial arterial occlusion visible on CT-angiography, MR-angiography or catheter digital subtraction angiography (DSA) in the middle cerebral, anterior or posterior cerebral artery. The occlusion may be primary or secondary (ie following initial mechanical thrombectomy of a large vessel occlusion) Exclusion Criteria: * Intracranial hemorrhage (ICH) identified by CT or MRI * Rapidly improving symptoms at the discretion of the investigator * Pre-stroke mRS score of ≥ 3 (indicating functional dependence) * Frank hypodensity in \>1/3 of the affected arterial territory on non-contrast CT * CT Perfusion ischemic core volume \> 100 ml * Known automated implantable cardiac defibrillator, pacemaker, cerebral aneurysm clip, cochlear implant, cranial neurostimulator or other device implant that is incompatible with the external magnetic field * Known allergy or sensitivity to iron * Known hemochromatosis, or known liver disease such as cirrhosis. * Known aortic dissection * Suspected septic embolization * Contra indication to imaging with contrast agents * Pregnant or lactating women * Any terminal illness such that patient would not be expected to survive more than 6 months * Current participation in another investigational drug or device treatment study * Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.